{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T05:06:42Z","timestamp":1649135202741},"reference-count":18,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"DOI":"10.1007\/s10165-012-0819-2","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T20:39:02Z","timestamp":1357763942000},"source":"Crossref","is-referenced-by-count":2,"title":["The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group"],"prefix":"10.1093","author":[{"given":"Masahiro","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Horiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Katsurahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsumasa","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"819_CR1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.joca.2007.06.014","volume":"15","author":"W Zhang","year":"2007","unstructured":"Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil. 2007;15:981\u20131000.","journal-title":"Osteoarthr Cartil"},{"key":"819_CR2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.2010.128660","volume":"70","author":"G Burmester","year":"2011","unstructured":"Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011;70:818\u201322.","journal-title":"Ann Rheum Dis"},{"key":"819_CR3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"23","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;23:1520\u20138.","journal-title":"N Engl J Med"},{"key":"819_CR4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247\u201355.","journal-title":"JAMA"},{"key":"819_CR5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.cgh.2007.06.009","volume":"5","author":"JL Goldstein","year":"2007","unstructured":"Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol. 2007;5:1167\u201374.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"819_CR6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","volume":"282","author":"LS Simon","year":"1999","unstructured":"Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921\u20138.","journal-title":"JAMA"},{"key":"819_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1756-185X.2010.01463.x","volume":"13","author":"R Cheung","year":"2010","unstructured":"Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, et al. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis. 2010;13:151\u20137.","journal-title":"Int J Rheum Dis"},{"key":"819_CR8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3164\/jcbn.40.148","volume":"40","author":"SH Park","year":"2007","unstructured":"Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J Clin Biochem Nutr. 2007;40:148\u201355.","journal-title":"J Clin Biochem Nutr"},{"key":"819_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"E Inoue","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407\u20139.","journal-title":"Ann Rheum Dis"},{"key":"819_CR10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.162.2.169","volume":"162","author":"DY Graham","year":"2002","unstructured":"Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. NSAID-Associated Gastric Ulcer Prevention Study Group: ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169\u201375.","journal-title":"Arch Intern Med"},{"key":"819_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1023\/B:DDAS.0000017439.60943.5c","volume":"49","author":"AS Tarnawski","year":"2004","unstructured":"Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and COX-2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202\u20139.","journal-title":"Dig Dis Sci"},{"key":"819_CR12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.bcp.2010.01.030","volume":"79","author":"T Ishihara","year":"2010","unstructured":"Ishihara T, Tanaka K, Tashiro S, Yoshida K, Mizushima T. Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. Biochem Pharmacol. 2010;79:1622\u201333.","journal-title":"Biochem Pharmacol"},{"key":"819_CR13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","volume":"369","author":"FK Chan","year":"2007","unstructured":"Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621\u20136.","journal-title":"Lancet"},{"key":"819_CR14","first-page":"467","volume":"29","author":"F Wolfe","year":"2002","unstructured":"Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol. 2002;29:467\u201373.","journal-title":"J Rheumatol"},{"key":"819_CR15","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947\u201353.","journal-title":"JAMA"},{"key":"819_CR16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2004.01935.x","volume":"19","author":"FK Chan","year":"2004","unstructured":"Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19:1051\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"819_CR17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","volume":"101","author":"JM Scheiman","year":"2006","unstructured":"Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701\u201310.","journal-title":"Am J Gastroenterol"},{"key":"819_CR18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10165-011-0524-6","volume":"22","author":"S Tsuji","year":"2012","unstructured":"Tsuji S, Miyoshi H, Tomita T, Nakase T, Hamada M, Oomae T, et al. Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. Mod Rheumatol. 2012;22:353\u201362.","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-012-0819-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:25:50Z","timestamp":1646843150000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-012-0819-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":18,"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s10165-012-0819-2","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]}}}